Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2007

Bradley to Make a $7M Milestone Payment to BioSante and Antares

  • The approval of a treatment for hot flashes in menopausal women triggered a $7-million milestone payment from Bradley Pharmaceuticals to two companies.

    In November 2006, Bradley Pharmaceuticals signed a marketing agreement with BioSante and its licensor, Antares Pharma, related to Elestrin in the U.S., through Bradley's Kenwood Therapeutics division.

    Under the terms of this agreement, BioSante will receive $5.25 million and Antares will get $1.75 million. Additionaly payments will be made to both companies in December 2007.

    BioSante reports that it retains the right to receive up to an additional $30 million upon the achievement of certain sales-based milestones. Antares says that regulatory- and sales-based payments could bring its total up to more than $13 million. The company will also receive a percentage of the royalties on third-party sales of Elestrin.

    Bradley expects to launch Elestrin in mid-2007 into the $1.3 billion estrogen market. It is a low-dose transdermal estradiol therapy delivered in Antares’ Advanced Transdermal Delivery gel system.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »